OneTwenty develops bioX®, a machine learning-based platform that enhances glycemic control through real-time data analysis from insulin pumps and smart pens. The technology addresses the inadequacies in current diabetes management by providing personalized insights and predictive modeling to improve patient outcomes and reduce hypoglycemia risk.
Funding
$890K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for managing diabetes often fall short, leaving many individuals struggling to maintain optimal glycemic control, especially in stressful or unusual situations. Traditional approaches lack the real-time, personalized insights needed to effectively manage insulin delivery and predict potential health events.
Solution
OneTwenty offers bioX®, a machine-learning platform designed to enhance glycemic control through real-time analysis of data from insulin pumps, smart pens, and continuous glucose monitors (CGMs). bioX® uses this data to create a personalized digital twin for each user, modeling individual reactions, patterns, and dependencies to predict biomarkers, patient-reported outcomes, and health-impacting events. The platform's bioX® neoAP application powers learning closed-loop automatic insulin delivery (LCL-AID) systems, while bioX® sensAI optimizes data translation from raw sensor data into target biomarkers with improved accuracy. bioX® is designed to be lightweight and deployable directly to systems-on-chips (SoCs), with the option to offload computationally intensive tasks to connected devices or the cloud.
Target Audience
The primary target audience includes individuals with Type 1 and Type 2 diabetes using insulin pumps, smart pens, and CGMs, as well as medical device companies seeking to integrate advanced glycemic control technology into their products.
Features
- Learning closed-loop automatic insulin delivery (LCL-AID) system powered by bioX® neoAP, compatible with connected insulin pumps and MDI solutions
- Digital twin engine (bioX® DT) that models individual metabolism and predicts health events based on personalized health data streams
- Sensor optimization (bioX® sensAI) for enhanced accuracy in biomarker data translation from invasive and non-invasive sensors
- Built on a foundation of over 4.4 million CGM hours of data collected from clinical studies and real-world data donations
- Ultra-lightweight design for deployment directly to SoCs, with flexible options for computational offloading
- Complete data infrastructure with MLOps for cost-efficient integration and scalability
- HIPAA-compliant data storage with customizable data storage locations and optional Samsung Knox and iOS hardware-accelerated encryption
- Extensively tested using FDA-approved procedures and in-silico trials simulating over 100,000 hours of closed-loop application